<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00355576</url>
  </required_header>
  <id_info>
    <org_study_id>AAAB6334</org_study_id>
    <secondary_id>ALSA ID#920</secondary_id>
    <nct_id>NCT00355576</nct_id>
  </id_info>
  <brief_title>Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis</brief_title>
  <official_title>Phase II Combination Therapy Selection Trial in Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ALS Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to compare two combinations of drugs, minocycline and creatine&#xD;
      or celecoxib and creatine, in a phase II trial designed to determine which combination is&#xD;
      more effective for ALS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Excess free radicals, energy mishandling, excitotoxicity, activation of cell death pathways&#xD;
      and inflammation likely all contribute to neurodegeneration in ALS. Past trials may have been&#xD;
      negative in part because they tested single agents, usually influencing only one mechanism of&#xD;
      cell death. Combinations of agents that affect different and multiple mechanisms of&#xD;
      neurodegeneration may be necessary to reach meaningful outcomes in trials of ALS.&#xD;
&#xD;
      This trial has several unique features. First, it compares the neuroprotective potential of&#xD;
      two combinations of agents that impact multiple mechanisms of cell death. The combinations of&#xD;
      minocycline/creatine and celecoxib/creatine are the only agents that have had additive&#xD;
      effects in the mouse model of ALS, reducing neurodegeneration and prolonging survival more&#xD;
      than individual agents alone. Second, it uses an important new phase II selection trial&#xD;
      design to determine which combination is superior. Not only does this trial test combination&#xD;
      therapy, but there is no placebo, so everyone who enrolls in the trial will receive active&#xD;
      treatment.&#xD;
&#xD;
      Minocycline, creatine and celecoxib have been tested individually and have been shown to be&#xD;
      safe in patients with ALS. This will be the first time human trials will be conducted with&#xD;
      combinations of minocycline/creatine and celecoxib/creatine.&#xD;
&#xD;
      We will compare combinations of drugs in a phase II trial design to determine which&#xD;
      combination is superior. If successful, this trial will lead directly to a phase III trial of&#xD;
      the selected combination. If the design is found useful, this trial will lead to larger phase&#xD;
      II selection trials assessing greater numbers of agents simultaneously, thereby improving the&#xD;
      efficiency of drug screening in ALS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ALS Functional Rating Scale Revised (ALSFRS-R) completed monthly during trial.</measure>
    <time_frame>Up to 6 months from the start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity, Quality of Life, Timed Get Up and Go performed monthly. Survival and measures of safety throughout the trial.</measure>
    <time_frame>Up to 6 months from the start of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>Minocycline + Creatine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Minocycline 100 mg BID and Creatine 10 g BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celecoxib + Creatine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Celecoxib 400 mg BID and Creatine 10 g BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>Celecoxib 400 mg BID with creatine 10 g BID if randomized to the Celecoxib + Creatine study arm.</description>
    <arm_group_label>Celecoxib + Creatine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Creatine</intervention_name>
    <description>10 g BID for either study arm</description>
    <arm_group_label>Celecoxib + Creatine</arm_group_label>
    <arm_group_label>Minocycline + Creatine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minocycline</intervention_name>
    <description>Minocycline 100 mg BID with creatine 10 g BID if randomized to the Minocycline + Creatine study arm</description>
    <arm_group_label>Minocycline + Creatine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A clinical diagnosis of possible, laboratory-supported probable, probable or definite&#xD;
             ALS, according to modified EL Escorial criteria&#xD;
&#xD;
          -  FVC greater or equal to 60% at the screening visit&#xD;
&#xD;
          -  Symptom onset within 5 years&#xD;
&#xD;
          -  21 to 85 years of age&#xD;
&#xD;
          -  If patients are taking riluzole, they must be on a stable dose for at least the past&#xD;
             thirty days&#xD;
&#xD;
          -  A woman of childbearing age, must be nonlactating and surgically sterile or using an&#xD;
             effective method of birth control (barrier method) and have a negative pregnancy test&#xD;
&#xD;
          -  Able to maintain adequate hydration levels defined as 6-8 cups (8ounces/cup) of water&#xD;
             or a non-caffeinated beverage per day&#xD;
&#xD;
          -  Willing and able to give signed informed consent that has been approved by an&#xD;
             Institutional Review Board (IRB)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Tracheotomy and mechanical ventilation&#xD;
&#xD;
          -  Diagnosis of other neurodegenerative diseases (Parkinson's disease, Alzheimer's&#xD;
             disease, etc)&#xD;
&#xD;
          -  Unstable medical illness (coronary artery disease, advanced cancer, active esophageal&#xD;
             or gastroduodenal ulcers, etc) in the last one year&#xD;
&#xD;
          -  Systemic Lupus Erythematosis&#xD;
&#xD;
          -  FVC &lt; 60%&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Allergy to minocycline, tetracyclines, celecoxib, sulfonamides, NSAIDS, or creatine&#xD;
&#xD;
          -  History of congestive heart failure&#xD;
&#xD;
          -  Renal disease [baseline Cr &gt; 1.5 (men) or 1.2 (women)]&#xD;
&#xD;
          -  History of significant hepatic disease (baseline AST/ALT or bilirubin &gt; 1.5x normal)&#xD;
&#xD;
          -  Use of an investigational agent within thirty days of enrollment&#xD;
&#xD;
          -  First degree relative with ALS or gene identified familial ALS&#xD;
&#xD;
          -  Inability or unwillingness to maintain adequate daily hydration (defined above)&#xD;
&#xD;
          -  Limited mental capacity such that the patient cannot provide written informed consent&#xD;
             or comply with evaluation procedures.&#xD;
&#xD;
          -  History of recent alcohol or drug abuse or noncompliance with treatment or other&#xD;
             experimental protocols.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul H Gordon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Phoenix Neurological Associates</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Georgia</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMDNJ</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.columbiaals.org</url>
    <description>Eleanor and Lou Gehrig MDA/ALS Research Center at Columbia University website</description>
  </link>
  <link>
    <url>http://www.alsa.org</url>
    <description>ALS Association Website</description>
  </link>
  <reference>
    <citation>Klivenyi P, Kiaei M, Gardian G, Calingasan NY, Beal MF. Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem. 2004 Feb;88(3):576-82.</citation>
    <PMID>14720207</PMID>
  </reference>
  <reference>
    <citation>Zhang W, Narayanan M, Friedlander RM. Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol. 2003 Feb;53(2):267-70.</citation>
    <PMID>12557297</PMID>
  </reference>
  <reference>
    <citation>Cheung YK, Gordon PH, Levin B. Selecting promising ALS therapies in clinical trials. Neurology. 2006 Nov 28;67(10):1748-51. Review.</citation>
    <PMID>17130405</PMID>
  </reference>
  <verification_date>January 2011</verification_date>
  <study_first_submitted>July 21, 2006</study_first_submitted>
  <study_first_submitted_qc>July 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2006</study_first_posted>
  <last_update_submitted>January 31, 2011</last_update_submitted>
  <last_update_submitted_qc>January 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>Paul H. Gordon</name_title>
    <organization>Columbia University Medical Center</organization>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Celecoxib</keyword>
  <keyword>Creatine</keyword>
  <keyword>Minocycline</keyword>
  <keyword>Combination</keyword>
  <keyword>Selection</keyword>
  <keyword>ALS</keyword>
  <keyword>Motor Neuron Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

